Why Did INmune Bio Plunge 17.56%? Q2 Loss Widens 110%

On August 8, 2025, INmune Bio's stock experienced a significant drop of 17.56% in pre-market trading, reflecting a notable decline in investor sentiment.

INmune Bio reported a substantial widening of its Q2 loss by 110%, continuing to generate no meaningful revenue as it remains in the clinical-stage of development. The company's cash and cash equivalents stood at $33.4 million by the end of June, indicating a stable financial position despite the widening loss.

During the Q2 2025 earnings call, the company provided insights into its financial performance and strategic direction. The call highlighted the ongoing challenges faced by the company in its clinical-stage development, which has contributed to the widening loss and lack of revenue.